{
  "title": "Healthcare's Balance Between Science and Commerce",
  "description": "Jami Rubin, business unit leader of the Healthcare Research Group for Goldman Sachs Research, discusses top trends in healthcare, including progress in the fight against cancer, diabetes and Alzheimer's, cutting-edge science in gene therapy and gene editing, and how the drug industry is dealing with  debates over pricing and mergers.\n\n\nThis podcast was recorded on June 17, 2016.\n\n\nAll price references and market forecasts correspond to the date of this recording.\n\n\nThis podcast should not be copied, distributed, published or reproduced, in whole or in part. The information contained in this podcast does not constitute research or a recommendation from any Goldman Sachs entity to the listener. Neither Goldman Sachs nor any of its affiliates makes any representation or warranty, as to the accuracy or completeness of the statements or any information contained in this podcast and any liability therefor (including in respect of direct, indirect or consequential loss or damage) is expressly disclaimed. The views expressed in this podcast are not necessarily those of Goldman Sachs, and Goldman Sachs is not providing any financial, economic, legal, accounting or tax advice or recommendations in this podcast.  In addition, the receipt of this podcast by any listener is not to be taken as constituting the giving of investment advice by Goldman Sachs to that listener, nor to constitute such person a client of any Goldman Sachs entity.\n\n\nCopyright 2016 Goldman Sachs. All rights reserved.",
  "pubDate": "Wed, 13 Jul 2016 20:10:00 -0000",
  "itunes:episodeType": "full",
  "itunes:author": "Goldman Sachs",
  "itunes:image": "",
  "itunes:subtitle": "An exchange on trends in the healthcare sector",
  "itunes:summary": "Jami Rubin, business unit leader of the Healthcare Research Group for Goldman Sachs Research, discusses top trends in healthcare, including progress in the fight against cancer, diabetes and Alzheimer's, cutting-edge science in gene therapy and gene editing, and how the drug industry is dealing with  debates over pricing and mergers.\n\n\nThis podcast was recorded on June 17, 2016.\n\n\nAll price references and market forecasts correspond to the date of this recording.\n\n\nThis podcast should not be copied, distributed, published or reproduced, in whole or in part. The information contained in this podcast does not constitute research or a recommendation from any Goldman Sachs entity to the listener. Neither Goldman Sachs nor any of its affiliates makes any representation or warranty, as to the accuracy or completeness of the statements or any information contained in this podcast and any liability therefor (including in respect of direct, indirect or consequential loss or damage) is expressly disclaimed. The views expressed in this podcast are not necessarily those of Goldman Sachs, and Goldman Sachs is not providing any financial, economic, legal, accounting or tax advice or recommendations in this podcast.  In addition, the receipt of this podcast by any listener is not to be taken as constituting the giving of investment advice by Goldman Sachs to that listener, nor to constitute such person a client of any Goldman Sachs entity.\n\n\nCopyright 2016 Goldman Sachs. All rights reserved.",
  "content:encoded": "<p>\n        \n        \n        \n        \n        \n        \n        \n        \n        \n        \n        Jami Rubin, business unit leader of the Healthcare Research Group for Goldman Sachs Research, discusses top trends in healthcare, including progress in the fight against cancer, diabetes and Alzheimer's, cutting-edge science in gene therapy and gene editing, and how the drug industry is dealing with  debates over pricing and mergers.\n</p><p>\nThis podcast was recorded on June 17, 2016.\n</p><p>\nAll price references and market forecasts correspond to the date of this recording.\n</p><p>\nThis podcast should not be copied, distributed, published or reproduced, in whole or in part. The information contained in this podcast does not constitute research or a recommendation from any Goldman Sachs entity to the listener. Neither Goldman Sachs nor any of its affiliates makes any representation or warranty, as to the accuracy or completeness of the statements or any information contained in this podcast and any liability therefor (including in respect of direct, indirect or consequential loss or damage) is expressly disclaimed. The views expressed in this podcast are not necessarily those of Goldman Sachs, and Goldman Sachs is not providing any financial, economic, legal, accounting or tax advice or recommendations in this podcast.  In addition, the receipt of this podcast by any listener is not to be taken as constituting the giving of investment advice by Goldman Sachs to that listener, nor to constitute such person a client of any Goldman Sachs entity.\n</p><p>\nCopyright 2016 Goldman Sachs. All rights reserved.\n\n            \n      \n      \n      \n      \n      \n      \n      \n      \n      \n      \n      </p>",
  "itunes:duration": 1187,
  "guid": "http://www.goldmansachs.com/s/podcast-exchanges/exchanges-episode-42.mp3",
  "enclosure": ""
}